Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin.
Here’s how the company did, compared to analysts’ consensus estimates from LSEG:
Earnings per share: 11 cents vs. 10 cents expected
Revenue: $481 million vs. $470 millionexpected
Revenue at the telehealth company increased 95% in the fourth quarter from $246.6 million during the same period last year, according to a release.
However, the company’s gross margin, or the profit left after accounting for the cost of goods sold, was 77%, while analysts polled by StreetAccount were expecting 78.4%.
It is the second big stock drop for Hims & Hers in a matter of days. The shares tumbled 26% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved.
In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk‘s blockbuster GLP-1 medications Ozempic and Wegovy. The company was a breakout star within the digital health sector in 2024, in part because of the success of its popular new weight loss offering.
The company said its GLP-1 offering generated more than $225 million in revenue in 2024. The stock climbed about 200% for the year.
Compounded drugs are custom-made alternatives to brand-name drugs designed to meet a specific patient’s needs, and compounders are allowed to produce them when brand-name treatments are in shortage. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
Hims & Hers said on the earnings call that as a result, compounded semaglutide will likely not be offered on the platform after the first quarter.
“We will have to start notifying customers in the coming month or two that they will need to start looking for alternative options on the commercial dosing,” Hims & Hers CEO Andrew Dudum said on the call. “I would suspect, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor.”
Some patients might still be able to access compounded semaglutide if it is clinically necessary, the company added.
The company’s weight loss offerings will primarily be composed of its oral medications and the generic medication liraglutide, which it plans to introduce on its platform this year. Excluding contributions from compounded semaglutide, Hims & Hers said it expects it weight loss offering will generate at least $725 million in revenue in 2025.
Hims & Hers also offers treatments for skin care, mental health, sexual health and hair care.
Revenue for non-GLP-1 products increased 43% to $1.2 billion for the full year, “meeting our previous 2025 revenue target a year early,” Chief Financial Officer Yemi Okupe said in a release.
“The success we are experiencing is a direct reflection of our improving ability to democratize access to high quality, personalized care across each of our specialties,” Okupe said.
Net income climbed to $26.01 million, or 11 cents per share, from $1.25 million, or 1 cent per share, a year prior. The company reported adjusted earnings of $54.1 million, meeting analysts’ estimates, according to StreetAccount.
For the first quarter, Hims & Hers expects to report revenue of $520 million to $540 million, while analysts were expecting $497 million. Adjusted earnings will be between $55 million and $65 million for the period, the company said.
Hims & Hers will host its quarterly call with investors at 5:00 p.m. ET.
— CNBC’s Brandon Gomez contributed to this report.
Apple shares popped 5% Wednesday, ahead of an Oval Office event touting an update to the company’s stated plans to spend and invest in the U.S.
CEO Tim Cook will join President Donald Trump for the announcement set for 4:30 p.m. ET.
Apple will up its previous commitment, made in February, from $500 billion to $600 billion over the next four years, a White House official told CNBC.
It will also announce a new manufacturing program called the American Manufacturing Program, the official said.
Cook has had a mixed relationship with Trump over the past year. While Trump has praised the Apple CEO in the past, in recent months he has said he has a “problem” with the executive and has pushed for Apple to assemble its iPhones in the U.S., not China or India.
Read more CNBC tech news
Apple faces over $1 billion in increased costs this quarter because of Trump’s tariffs on imports —primarily related to China — and Cook reminded investors last week that “the vast majority” of its products would be subject to pending new tariffs under a Section 232 investigation.
“We obviously try to optimize our supply chain, and ultimately we will do more in the United States,” Cook said.
Match Group shares popped more than 10% on Wednesday after the online dating company issued upbeat guidance and said new products are showing promise as it attempts to turnaround its business.
The Dallas-based company said it expected revenues between $910 million and $920 million in the current quarter, beating a $890 million estimate from analysts polled by FactSet.
“We are operating like a company that is just getting started, and we believe the best chapters of the category and company are still ahead,” said CEO Spencer Rascoff during an earnings call Tuesday. “We are moving with urgency, we are obsessed with the product and we are building for the long term.”
Over the last year, Match and the broader online dating industry have grappled with slowing user engagement. The company has added more tools and features to its apps, including Tinder and Hinge, to lure back customers, especially Gen Z.
Match has also been the target of activists investors such as Starboard Value, which has pushed the company to innovate, cut costs and improve profitability or consider going private.
In an effort to revamp its business, Match appointed Zillow co-founder Rascoff as its new CEO in February. Under his direction, the company has implemented new artificial intelligence-powered tools and slashed roles.
Match also added new features such as AI-powered discovery to many of its services and a double date feature on Tinder. Rascoff on Tuesday said that 90% or customers using this feature are under age 30.
The company will also target the younger market with features geared toward college students and is planning to reinvest $50 million into new product development, Rascoff said.
In 2026 and 2027, Rascoff said he expects AI innovation and international growth to expand its Hinge platform’s leadership as Tinder becomes a “low-pressure, serendipitous experience designed for Gen Z.” Hinge, he said, is also on track to deliver quarterly year-over-year growth in 2025.
“Across the board, we believe the category will enter a new era, with renewed trust, strong demand and long-term growth potential,” he said.
Match posted in-line earnings of 49 cents per share. Revenues reached $864, topping the $854 million expected by analysts.
OpenAI CEO Sam Altman speaks during the US Federal Reserve Board of Governors’ “Integrated Review of the Capital Framework for Large Banks Conference” at the Federal Reserve in Washington, DC, on July 22, 2025.
Mandel Ngan | AFP | Getty Images
OpenAI on Wednesday announced it will offer its ChatGPT Enterprise product to U.S. federal agencies for $1 through the next year, making its technology available to the federal executive branch workforce at “essentially no cost.”
The company has been working to deepen its ties to lawmakers and regulators in recent months, and it will open its first office in Washington, D.C., early next year.
OpenAI said participating agencies will get access to its frontier models through ChatGPT Enterprise, and it will also offer access to features like Advanced Voice Mode for an additional 60-day period.
The company has partnered with the U.S. General Services Administration to launch the initiative.
Read more CNBC tech news
“Helping government work better – making services faster, easier, and more reliable—is a key way to bring the benefits of AI to everyone,” OpenAI said in a blog post.
In June, OpenAI launched a new offering called OpenAI for Government and said it was awarded a contract of up to $200 million by the U.S. Department of Defense.
The company is currently engaging in talks with investors about a potential stock sale at a valuation of roughly $500 billion, as CNBC previously reported.
OpenAI announced a $40 billion funding round in March at a $300 billion valuation, by far the largest amount ever raised by a private tech company.